Mark Lebwohl

Summary

Publications

  1. ncbi request reprint Psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet 361:1197-204. 2003
  2. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
  3. doi request reprint From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies
    Jeremy Hugh
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York
    J Am Acad Dermatol 70:168-77. 2014
  4. ncbi request reprint Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Drugs Dermatol 6:428-35. 2007
  5. ncbi request reprint A clinician's paradigm in the treatment of psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Acad Dermatol 53:S59-69. 2005
  6. doi request reprint p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVA
    Yongyin Wang
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Photochem Photobiol 84:444-9. 2008
  7. doi request reprint Combining systemic retinoids with biologic agents for moderate to severe psoriasis
    Elizabeth C A Smith
    Department of Dermatology, Mount Sinai School of Medicine, New York, USA
    Int J Dermatol 47:514-8. 2008
  8. ncbi request reprint Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use
    Amy S Paller
    Department of Dermatology, Northwestern University s Feinberg Medical School Children s Memorial Hospital, 676 North St Clair St, Suite 1600, Chicago, IL 60611, USA
    Pediatrics 122:e1210-8. 2008
  9. ncbi request reprint The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, New York, USA
    Cutis 80:29-40. 2007
  10. doi request reprint Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
    Mark Lebwohl
    Mount Sinai School of Medicine, New York City, New York 10029, USA
    J Am Acad Dermatol 66:731-41. 2012

Detail Information

Publications96

  1. ncbi request reprint Psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet 361:1197-204. 2003
    ..Enhancements in topical therapy and phototherapy have also increased the armamentarium of treatments available for this disorder...
  2. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics
    Alice Gottlieb
    Department of Dermatology, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Am Acad Dermatol 58:851-64. 2008
    ..We will discuss the use of disease-modifying antirheumatic drugs and the biologic therapies in the treatment of patients with moderate to severe psoriatic arthritis...
  3. doi request reprint From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies
    Jeremy Hugh
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York
    J Am Acad Dermatol 70:168-77. 2014
    ..Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD...
  4. ncbi request reprint Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Drugs Dermatol 6:428-35. 2007
    ..Calcitriol 3 microg/g ointment has demonstrated good clinical efficacy as well as topical and systemic safety when used to treat psoriasis...
  5. ncbi request reprint A clinician's paradigm in the treatment of psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Acad Dermatol 53:S59-69. 2005
    ..Because some degree of therapy will always be necessary, ranging from maintenance of long-term remission to control of acute psoriasis flares, each patient requires an individualized plan...
  6. doi request reprint p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVA
    Yongyin Wang
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Photochem Photobiol 84:444-9. 2008
    ..We show that individually subcarcinogenic levels of BaP and UVA synergistically induce a novel p53-mutation fingerprint. This fingerprint could serve as a prognostic indicator for the development of BaP-UVA-induced skin tumors...
  7. doi request reprint Combining systemic retinoids with biologic agents for moderate to severe psoriasis
    Elizabeth C A Smith
    Department of Dermatology, Mount Sinai School of Medicine, New York, USA
    Int J Dermatol 47:514-8. 2008
    ..Although numerous data exist regarding the use of acitretin and biologic agent therapy alone for psoriasis, little is known about the efficacy, safety, and tolerability of acitretin combined with biologic agents...
  8. ncbi request reprint Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use
    Amy S Paller
    Department of Dermatology, Northwestern University s Feinberg Medical School Children s Memorial Hospital, 676 North St Clair St, Suite 1600, Chicago, IL 60611, USA
    Pediatrics 122:e1210-8. 2008
    ....
  9. ncbi request reprint The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, New York, USA
    Cutis 80:29-40. 2007
    ..It is notable that in subjects who were being treated with a variety of agents, the addition of clobetasol propionate spray 0.05% during the course of the study resulted in improvements in disease severity...
  10. doi request reprint Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
    Mark Lebwohl
    Mount Sinai School of Medicine, New York City, New York 10029, USA
    J Am Acad Dermatol 66:731-41. 2012
    ..Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of moderate-to-severe psoriasis...
  11. ncbi request reprint Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema
    Charles N Ellis
    Department of Dermatology, University of Michigan Medical School and Veterans Administration Medical Center, Ann Arbor, Michigan, USA
    Pharmacoeconomics 21:875-83. 2003
    ..The use of expert opinion is widespread in economic studies of healthcare utilisation; however, few studies have attempted to assess the validity of assumptions derived from such sources...
  12. ncbi request reprint Tacrolimus ointment in the treatment of eyelid dermatitis
    Amy Krupnick Freeman
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    Cutis 73:267-71. 2004
    ..In addition, none of the patients developed cataracts or glaucoma during the study. In summary, tacrolimus ointment 0.1% may be a safe and effective treatment option for patients with moderate to severe eyelid dermatitis...
  13. doi request reprint Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Acad Dermatol 63:571-9. 2010
    ..Patients with psoriasis tend to be overweight, and the efficacy of fixed-dose biologics may be compromised by high body weight...
  14. ncbi request reprint Overview on desonide 0.05%: a clinical safety profile
    Vicky Kwan Wong
    Department of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    J Drugs Dermatol 3:393-7. 2004
    ..The excellent safety profile of desonide revealed by this pharmacovigilance program is supported by a review of published clinical trial results...
  15. ncbi request reprint Tacrolimus ointment is effective for facial and intertriginous psoriasis
    Mark Lebwohl
    Mt Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 51:723-30. 2004
    ..Topical tacrolimus offers the potential for anti-inflammatory effect without the atrophy or other local side effects associated with the use of topical corticosteroids...
  16. ncbi request reprint Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study
    Carin Gribetz
    Mt Sinai School of Medicine, Department of Dermatology, New York, New York, USA
    J Am Acad Dermatol 51:731-8. 2004
    ..Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cytokine inhibitor, has been shown to be effective in the treatment of psoriasis when applied topically under occlusion...
  17. ncbi request reprint Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis
    Julian O Moore
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Carcinogenesis 27:1627-35. 2006
    ..The implications of our findings serve as compelling validation to our conclusions that genistein may serve as a potent chemopreventive agent against photocarcinogenesis...
  18. ncbi request reprint Combination therapy to treat moderate to severe psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, Mt Sinai Medical Center, 5 E 98th Street, 12th Floor, New York, NY 10029 6574, USA
    J Am Acad Dermatol 50:416-30. 2004
    ....
  19. ncbi request reprint A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses
    Annemarie Uliasz
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cutis 81:517-9. 2008
    ..05% caused a significantly greater reduction in epidermal thickness compared with fluocinonide cream 0.1% when used twice daily for 2 weeks (P<.001). However, neither drug caused significant clinical signs of atrophy...
  20. doi request reprint Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis
    Danielle Levine
    Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    J Am Acad Dermatol 63:775-81. 2010
    ..By inhibiting proinflammatory cytokines such as interleukin-12, interleukin-23, and tumor necrosis factor-alfa, nicotinamide may enhance the efficacy of calcipotriene therapy when used in combination...
  21. ncbi request reprint New roles for systemic retinoids
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    J Drugs Dermatol 5:406-9. 2006
    ....
  22. ncbi request reprint No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA
    Arch Dermatol 141:861-4. 2005
    ..To determine the incidence of cutaneous squamous cell carcinoma (SCC) in patients with rheumatoid arthritis receiving etanercept, a tumor necrosis factor antagonist, for up to 5 years...
  23. ncbi request reprint Benzo[a]pyrene and its metabolites combined with ultraviolet A synergistically induce 8-hydroxy-2'-deoxyguanosine via reactive oxygen species
    Dayuan Gao
    Department of Dermatology, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1047, New York, NY 10029, USA
    Free Radic Biol Med 39:1177-83. 2005
    ..Additionally, singlet oxygen was found to play a major role in 8-OHdG induction by BPDE and UVA. These results suggest that BaP metabolites such as BPDE synergize with UVA radiation to produce ROS, which in turn induce DNA damage...
  24. ncbi request reprint Review of therapy of psoriasis: the prebiologic armamentarium
    David S Aaronson
    Mount Sinai School of Medicine, 5 East 98th Street, Box 1048, New York, NY 10029 6574, USA
    Dermatol Clin 22:379-88, viii. 2004
    ..With the creation of the newer"biologics," however, the treatment of psoriasis is being re-evaluated...
  25. ncbi request reprint Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature
    Caroline P Halverstam
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    J Cutan Med Surg 10:291-9. 2006
    ..Low-dose acitretin has been used for many years as monotherapy or in combination with other systemic therapies for psoriasis. Evidence to date suggests that the frequency of symptomatic bony effects is quite low in these patients...
  26. doi request reprint The use of the 308-nm excimer laser for the treatment of psoriasis
    Suhail M Hadi
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    Photomed Laser Surg 28:693-5. 2010
    ..The objective was to study the effectiveness of the 308-nm excimer laser for the treatment of various forms of localized stable psoriasis...
  27. ncbi request reprint Case studies in severe psoriasis: A clinical strategy
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, 1 Gustave Levy Place, Box 1047, New York, NY 10029 6574, USA
    J Dermatolog Treat 14:26-46. 2003
    ..The purpose of the algorithms is to make optimum use of phototherapy, traditional cytotoxic and immunosuppressive agents, retinoids, and newer biologic agents...
  28. doi request reprint Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses
    Joshua A Zeichner
    Mount Sinai Medical Center, New York, New York, USA
    J Am Acad Dermatol 60:59-62. 2009
    ..Imiquimod 5% cream applied twice weekly for 16 weeks is effective for treating actinic keratoses but may be limited by local side effects...
  29. ncbi request reprint A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes
    John Koo
    UCSF Psoriasis and Phototherapy Treatment Center, Department of Dermatology, University of California, San Francisco 94118, USA
    J Am Acad Dermatol 55:637-41. 2006
    ..The merit of topical sequential therapy involving clobetasol foam and calcipotriene ointment has not been experimentally demonstrated...
  30. ncbi request reprint The effect of weight on the efficacy of biologic therapy in patients with psoriasis
    Lily Clark
    Department of Dermatology at Columbia University, New York, New York, USA
    J Am Acad Dermatol 58:443-6. 2008
    ..Patients with psoriasis, in particular, tend to be above normal weight. Three of the 5 biologics used to treat psoriasis are fixed-dosed treatments: alefacept, etanercept, and adalimumab. Dosing regimens do not account for weight...
  31. ncbi request reprint A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis
    Jason J Emer
    Mount Sinai School of Medicine, Department of Dermatology, New York, NY 10029, USA
    J Drugs Dermatol 10:735-43. 2011
    ..Significant improvements were noted for all efficacy variables. In conclusion, a lipid-rich, non-steroidal, topical medical device cream was as effective in improving atopic dermatitis as pimecrolimus cream...
  32. doi request reprint Evaluation of sensory irritation caused by topical medications using a novel technique
    Annemarie Uliasz
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Dermatol 49:269-71. 2010
    ..The aim of this study was to evaluate and compare the sensory irritation caused by hydrocortisone butyrate lipocream 0.1% using a non-invasive and inexpensive technique...
  33. ncbi request reprint Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial
    Sewon Kang
    Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA
    Am J Clin Dermatol 6:245-53. 2005
    ..Recently, we conducted a 2-year placebo-controlled study of tretinoin emollient cream 0.05%, including histopathologic assessment of safety and analysis of markers of collagen deposition...
  34. ncbi request reprint A new standardized method of evaluating cutaneous irritation from topical medications
    Annemarie Uliasz
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cutis 82:75-7. 2008
    ..05%, was calculated to be 2.55. Our assay was able to detect and quantify even minimal cutaneous irritation secondary to application of topical medications...
  35. ncbi request reprint Potential complications associated with the use of biologic agents for psoriasis
    Joshua A Zeichner
    Department of Dermatology, Mount Sinai Medical Center, 5 East 98th Street, Box 1048, New York, NY 10029, USA
    Dermatol Clin 25:207-13, vii. 2007
    ..Both physicians and patients should be aware of the risks involved with each medicine so that the correct drug is chosen to suit each patient...
  36. ncbi request reprint Recent advances in medical dermatology
    Lily N Clark
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Dermatol 46:1005-10. 2007
    ....
  37. ncbi request reprint Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I
    David M Pariser
    Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA
    J Cutan Med Surg 9:303-12. 2005
    ..Effective psoriasis therapies are needed for long-term symptom control...
  38. ncbi request reprint Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas
    Amy Krupnick Freeman
    Mount Sinai School of Medicine, Department of Dermatology, New York, NY 10029, USA
    J Am Acad Dermatol 48:564-8. 2003
    ..In summary, tacrolimus 0.1% ointment may be a safe and effective treatment option for patients with psoriasis on the face, intertriginous areas, or both...
  39. ncbi request reprint Newly available treatments for psoriatic arthritis and their impact on skin psoriasis
    Hassan Galadari
    Department of Dermatology, Mt Sinai Medical Center, New York, NY 10029, USA
    Int J Dermatol 42:231-7. 2003
    ..TNF inhibitors represent new therapeutic options for patients with PsA. The potential advantages of treatment with etanercept and infliximab early in the disease course are discussed...
  40. ncbi request reprint Combining the new biologic agents with our current psoriasis armamentarium
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Am Acad Dermatol 49:S118-24. 2003
    ..Mechanisms of action of the biologic therapies suggest that there is potential for additive benefit when used in combination regimens...
  41. doi request reprint New biologics for psoriasis and psoriatic arthritis
    Mariya Rozenblit
    Mount Sinai School of Medicine, 5 E 98th Street, New York, NY 10029 6501, USA
    Dermatol Ther 22:56-60. 2009
    ..However, longer studies with radiographic evaluation will be required before their impact on joint destruction can be assessed...
  42. ncbi request reprint An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis
    Carin H Gribetz
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Acad Dermatol 53:73-5. 2005
    ..The efficacy and safety of one and two courses of alefacept have been demonstrated in phase 2 and 3 clinical trials, with a course of alefacept defined as 12 weeks of once-weekly treatment followed by 12 weeks of observation...
  43. ncbi request reprint Reduced burning and stinging associated with topical application of lactic acid 10% with strontium versus ammonium lactate 12%
    Madelaine Haddican
    Department of Dermatology, Mount Sinai Medical Center, New York, New York, USA
    Cutis 91:260-2. 2013
    ..0001). Based on the study results, lactic acid cream 10% with strontium causes less burning/stinging than ammonium lactate lotion 12%...
  44. doi request reprint Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    JAMA Dermatol 149:666-70. 2013
    ..Ingenol mebutate is the active agent (a macrocyclic diterpene ester) in the sap of the plant Euphorbia peplus. This herb has been used as a traditional remedy for several different skin lesions, including skin cancers...
  45. doi request reprint Ingenol mebutate gel for actinic keratosis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, USA
    N Engl J Med 366:1010-9. 2012
    ..We investigated the efficacy and safety of a new topical field therapy for actinic keratosis, ingenol mebutate gel (0.015% for face and scalp and 0.05% for trunk and extremities)...
  46. ncbi request reprint Topical calcitriol is degraded by ultraviolet light
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    J Invest Dermatol 121:594-5. 2003
    ..Calcipotriene, the only vitamin D analog already approved for psoriasis in the USA, has been used successfully in combination with ultraviolet B and psoralen plus ultraviolet A...
  47. doi request reprint Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
    Robert E Kalb
    Department of Dermatology State University of New York at Buffalo, School of Medicine and Biomedical Science, Buffalo, New York, USA
    J Am Acad Dermatol 60:824-37. 2009
    ..Methotrexate remains a valuable option for the treatment of psoriasis. This report will summarize studies regarding the use of methotrexate since the last guidelines were published in 1998...
  48. ncbi request reprint Combined subcarcinogenic benzo[a]pyrene and UVA synergistically caused high tumor incidence and mutations in H-ras gene, but not p53, in SKH-1 hairless mouse skin
    Yongyin Wang
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Cancer 116:193-9. 2005
    ..C-->T transitions were detected in p53 hot spots of exon 8 in 2 of 19 BaP-UVA-induced tumors but were not found in nontumor skin...
  49. ncbi request reprint Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Cutis 83:205-12. 2009
    ..Clinical improvement was maintained for up to 52 weeks, with no clinical effect on calcium homeostasis or other relevant laboratory test parameters...
  50. ncbi request reprint Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies
    Carin H Endzweig-Gribetz
    Department of Dermatology, Mount Sinai School of Medicine, One Gustave Levy Place, New York, New York 10029, USA
    J Cutan Med Surg 6:12-6. 2002
  51. ncbi request reprint Prominent mental (chin) crease: a new sign of pseudoxanthoma elasticum
    Mark Lebwohl
    Department of Dermatology at the Mount Sinai School of Medicine, USA
    J Am Acad Dermatol 48:620-2. 2003
    ..Mental creases commonly occur in patients with PXE. In young patients they are a sensitive and highly specific physical finding of this disorder. The presence of exaggerated mental creases is, thus, a useful physical marker for PXE...
  52. ncbi request reprint Proven efficacy of tacrolimus for facial and intertriginous psoriasis
    Mark Lebwohl
    Arch Dermatol 141:1154. 2005
  53. ncbi request reprint A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis
    Mark Lebwohl
    Departments of Dermatology, Mount Sinai Medical Center, New York, NY 10029 6574, USA
    Int J Dermatol 41:269-74. 2002
    ..A clobetasol propionate foam product is as effective as clobetasol propionate solution in the treatment of scalp psoriasis...
  54. ncbi request reprint Treatment of mycosis fungoides with oral bexarotene combined with PUVA
    Dana Kaslow Stern
    Mount Sinai Medical Center, One Gustave L Place, New York, NY 10029, USA
    J Drugs Dermatol 1:134-6. 2002
    ..Our patient's response to a novel regimen of low dose bexarotene combined with PUVA has been excellent and suggests that this regimen may be a useful method for treatment of MF...
  55. doi request reprint Iatrogenic effects of biologics for psoriasis
    Mary L Stevenson
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Dermatol 29:614-21. 2011
    ..Focus is placed on antitumor necrosis factor agents, because they are the most studied and commonly used agents, as well as T-cell modulators and interleukin inhibitors...
  56. ncbi request reprint Water content and other aspects of brittle versus normal fingernails
    Dana Kazlow Stern
    Mount Sinai Hospital, Mount Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 57:31-6. 2007
    ..Previous authors have claimed that dehydration of the nail plate causes brittle nails. Some experts claim that normal nails contain 18% water, and brittle nails contain less than 16%...
  57. ncbi request reprint Impaired skin barrier function in dermatologic disease and repair with moisturization
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    Cutis 76:7-12. 2005
    ....
  58. ncbi request reprint Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Am Acad Dermatol 50:714-21. 2004
    ..The immune system plays a critical role in the development and pathogenesis of actinic keratosis (AK). Imiquimod has been shown to stimulate the cutaneous immune response and be effective for the treatment of nonmelanoma skin cancers...
  59. doi request reprint Nonstandard and off-label therapies for psoriasis
    Caroline P Halverstam
    Department of Dermatology, Mount Sinai School of Medicine, Box 1048, New York, NY 10029 6574, USA
    Clin Dermatol 26:546-53. 2008
    ..Other unconventional therapies include climatotherapy at the Dead Sea and grenz ray therapy...
  60. ncbi request reprint Innovations in the treatment of psoriasis
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Am Acad Dermatol 51:S40-1. 2004
  61. ncbi request reprint Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome
    Marvin J Rapaport
    Department of Dermatology, UCLA School of Medicine, Los Angeles, California, USA
    Clin Dermatol 21:201-14. 2003
  62. ncbi request reprint Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis
    Amylynne Frankel
    Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, New York, NY 10029, USA
    J Drugs Dermatol 10:666-72. 2011
    ..This study confirmed that pimecrolimus cream 1% and the medical device foam work well in the treatment of AD in both adults and children with no associated adverse effects...
  63. doi request reprint Alefacept: where it stands today
    Jinan Chaarani
    Department of Dermatology, Mount Sinai School of Medicine, 5 East 98th Street, NY 10029, USA
    Expert Opin Drug Metab Toxicol 6:355-61. 2010
    ..It selectively reduces CD45RO(+) memory T cells and inhibits T-cell activation. Clinical data support its safety and efficacy in a substantial subset of patients with psoriasis...
  64. ncbi request reprint Inhibition of ultraviolet light-induced oxidative events in the skin and internal organs of hairless mice by isoflavone genistein
    Huachen Wei
    Department of Dermatology, Box 1047, Mount Sinai School of Medicine, One Gustave Levy Place, 1425 Madison Avenue, New York, NY 10029, USA
    Cancer Lett 185:21-9. 2002
    ..Thus, the antioxidative properties of genistein may explain for the mechanisms of anti-photocarcinogenic action of genistein...
  65. ncbi request reprint Imiquimod cream in the treatment of actinic keratoses
    Andrea Persaud
    Department of Dermatology, The Mount Sinai School of Medicine of New York University, New York, NY 1029, USA
    J Am Acad Dermatol 47:S236-9. 2002
    ..Treatments were well tolerated. Imiquimod cream appears to be effective in the treatment of actinic keratoses. The main adverse effect is local inflammation, which can be avoided by reducing the frequency of application...
  66. doi request reprint Cutaneous manifestations of cardiovascular diseases
    Annemarie Uliasz
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Dermatol 26:243-54. 2008
    ..This article discusses a number of cardiac disorders with prominent skin findings in addition to general dermatologic signs suggestive of cardiovascular disease...
  67. ncbi request reprint From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis
    Mark Lebwohl
    Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 58:94-105. 2008
    ..Biologics are widely used in the treatment of psoriasis and psoriatic arthritis...
  68. ncbi request reprint Use and abuse of topical corticosteroids in infections of the skin and related structures
    Vicky Kwan Wong
    Mount Sinai School of Medicine, 5 East 98th Street, 12th Floor, Box 1048, New York, NY 10029, USA
    J Drugs Dermatol 2:268-76. 2003
    ....
  69. ncbi request reprint Protective effects of lycopene against ultraviolet B-induced photodamage
    Zsuzsanna Fazekas
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nutr Cancer 47:181-7. 2003
    ....
  70. ncbi request reprint An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Dermatol 139:719-27. 2003
    ....
  71. ncbi request reprint The use of systemic immune moderators in dermatology: an update
    Dana Kazlow Stern
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Dermatol Clin 23:259-300. 2005
    ..This article reviews the pharmacology, mechanism of action, side effects, and clinical applications of these therapies...
  72. ncbi request reprint Oral phosphate binders in the treatment of pseudoxanthoma elasticum
    Daniel W Sherer
    Mount Sinai School of Medicine, New York, New York, USA
    J Am Acad Dermatol 53:610-5. 2005
    ..Normalization of the serum calcium-phosphate product through hemodialysis in a previous patient with perforating periumbilical PXE and elevated serum phosphate resulted in regression of skin lesions...
  73. pmc A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, New York, NY, USA
    MedGenMed 8:8. 2006
    ..Overall, TCIs have been shown to be an effective and valuable treatment option for AD...
  74. ncbi request reprint Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis
    Charles N Ellis
    Department of Dermatology, University of Michigan Medical School, Ann Arbor 48109 0314, USA
    J Am Acad Dermatol 48:553-63. 2003
    ..Few cost-effectiveness analyses have been conducted on topical therapies for atopic dermatitis...
  75. ncbi request reprint Vitamin D and topical therapy
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine, New York, New York, USA
    Cutis 70:5-8. 2002
    ..05% ointment and cream have been shown to be compatible with calcipotriene for up to 2 weeks. The compatibility of calcipotriene and halobetasol permits the use of these agents together...
  76. ncbi request reprint Effects of the isoflavone 4',5,7-trihydroxyisoflavone (genistein) on psoralen plus ultraviolet A radiation (PUVA)-induced photodamage
    Eileen Q Shyong
    Department of Dermatology, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Carcinogenesis 23:317-21. 2002
    ..005). These results indicate that genistein protects the skin from PUVA-induced photodamage...
  77. ncbi request reprint Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial
    Mark Lebwohl
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Dermatol 43:17-20. 2004
    ..Ciclopirox is a synthetic, hydroxypyridone-derived, broad-spectrum antifungal agent with anti-inflammatory properties...
  78. ncbi request reprint Mammographic findings in pseudoxanthoma elasticum
    Lionel Bercovitch
    Department of Dermatology, Rhode Island Hospital and Brown Medical School, Providence, USA
    J Am Acad Dermatol 48:359-66. 2003
    ....
  79. ncbi request reprint The combination of benzo[a]pyrene and ultraviolet A causes an in vivo time-related accumulation of DNA damage in mouse skin
    Rao Saladi
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Photochem Photobiol 77:413-9. 2003
    ..80). These results indicate that genetic damage caused by exposures to BaP plus UVA accumulates with time and increases the potential for inductive events leading to carcinogenesis and tumor formation...
  80. ncbi request reprint Should we switch from combination UVA/UVB phototherapy units to narrowband UVB?
    Mark Lebwohl
    Department of Dermatology, The Mount Sinai School of Medicine of NYU, 5 East 98th Street, Box 1048, New York, NY 10029 6574, USA
    Photodermatol Photoimmunol Photomed 18:44-6; discussion 47-9. 2002
  81. ncbi request reprint Pseudoxanthoma elasticum: Temporary treatment of chin folds and lines with injectable collagen
    Hassan Galadari
    Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Am Acad Dermatol 49:S265-6. 2003
    ..We report 2 patients with pseudoxanthoma elasticum who had characteristic rhytides and horizontal creases of the chin ("mental" creases). Rhytides and horizontal creases were successfully treated with injectable collagen...
  82. ncbi request reprint Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody
    Alice B Gottlieb
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    J Am Acad Dermatol 47:692-700. 2002
    ..The serum half-life of IDEC-114 was approximately 13 days. A single dose of IDEC-114 appears to be safe and well tolerated and has promising clinical activity in psoriasis...
  83. ncbi request reprint New developments in the treatment of psoriasis
    Mark Lebwohl
    Arch Dermatol 138:686-8. 2002
  84. ncbi request reprint Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis
    Jean Paul Ortonne
    hopital l Archet II, 15 Rue de Saint Antoine de Ginestiere, BP 079, Nice, France
    Eur J Dermatol 13:117-23. 2003
    ..These results provide further support for the deleterious roles of CD4+ and CD8+ memory T-cell subpopulations in psoriasis pathogenesis...
  85. ncbi request reprint Potential future dermatological indications for tacrolimus ointment
    Thomas Ruzicka
    Department of Dermatology, University of Dusseldorf, Moorenstr 5, 40225 Dusseldorf, Germsny
    Eur J Dermatol 13:331-42. 2003
    ..It also provides recommendations for future clinical studies with tacrolimus ointment...
  86. ncbi request reprint A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
    Mark Lebwohl
    Mt Sinai School of Medicine, New York 10029 6574, USA
    N Engl J Med 349:2004-13. 2003
    ..Efalizumab, a humanized monoclonal antibody, binds to the alpha subunit (CD11a) of LFA-1 and inhibits the activation of T cells...
  87. ncbi request reprint Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey
    Elizabeth J Horn
    National Psoriasis Foundation, Portland, Oregon 97223 7195, USA
    J Am Acad Dermatol 57:957-62. 2007
    ..We sought to assess whether patients with psoriasis with moderate or severe disease are being treated with systemic therapy...
  88. ncbi request reprint The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 54:61-3. 2006
    ..30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses...
  89. doi request reprint Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle
    Debra Breneman
    University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    J Am Acad Dermatol 58:990-9. 2008
    ..Intermittent dosing of a topical calcineurin inhibitor for preventing atopic dermatitis (AD) disease relapse in patients with stabilized AD has not been evaluated...
  90. ncbi request reprint A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
    Gerald G Krueger
    University of Utah, Salt Lake City, USA
    N Engl J Med 356:580-92. 2007
    ..Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis...
  91. ncbi request reprint Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects
    Clark C Otley
    Division of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dermatol Surg 32:562-8. 2006
    ..A patient's intolerance of the mucocutaneous effects of retinoid therapy or abnormal laboratory findings may hamper continuous therapy...
  92. ncbi request reprint Relapse, rebound, and psoriasis adverse events: an advisory group report
    Wayne Carey
    Royal Victoria Hospital, Montreal, Quebec, Canada
    J Am Acad Dermatol 54:S171-81. 2006
    ....
  93. doi request reprint Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    Kim A Papp
    Probity Medical Research, Waterloo and University of Western Ontario, London, ON, Canada
    Lancet 371:1675-84. 2008
    ..This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders...
  94. ncbi request reprint Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept
    Joshua A Zeichner
    J Am Acad Dermatol 54:S120-1. 2006
  95. ncbi request reprint Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    Alice B Gottlieb
    Clinical Research Center, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901 0019, USA
    Clin Immunol 111:28-37. 2004
    ..Reduction in lesional, activated T cells induces improvement in psoriatic plaques. Galiximab (IDEC-114), an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation...
  96. doi request reprint Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Alan Menter
    Baylor University Medical Center, Dallas, Texas, USA
    J Am Acad Dermatol 58:826-50. 2008
    ..Finally, we will discuss the safety and efficacy of the biologic treatments used to treat patients with psoriasis...